Moleculin ASCO data: Annamycin shows no cardiotoxicity at high cumulative doses

Moleculin Biotech, Inc.

Pooled analysis of 90 patients: no significant LVEF change (mean diff -0.12%, p=0.84) across doses up to 2,970 mg/m².
Independent Cleveland Clinic review confirms no drug-induced cardiotoxicity across ECGs, biomarkers, and adverse events.
Phase 1b/2 AML study achieved 50% CR, 60% CRc, median overall survival 12.39 months; 50% of responders received transplant.
Pivotal Phase 2b/3 MIRACLE trial unblinding of first 45 patients on track for June 2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.